BIO profile: Nucleus network: networking clinical trials
20 April, 2007 by Fiona WylieWhile Australia has always had a strong and influential basic science base, getting candidates through the trials process to market has long been seen as our stumbling block. A not-for-profit clinical trial network is set to change all of that.
BIO profile: Q-Pharm expands service range
20 April, 2007 by Staff WritersClinical trials specialist Q-Pharm has recently forged two important collaborations with international companies which will enable it to extend its services.
BIO profile: Queensland Clinical Trials Network
20 April, 2007 by Staff WritersThe not-for-profit Queensland Clinical Trials Network will be exhibiting at BIO 2007.
BIO profile: Hit and hit again for Bionomics
18 April, 2007 by Kate McDonaldBionomics has some good news to take to BIO 2007 from preclinical trials of its candidate vascular disruption agent.
BIO profile: Beta agonists for metabolic modification
16 April, 2007 by Kate McDonaldWest Australian animal health company Stirling Products is developing a compound for increased muscle production and reduced fat in livestock that also has applications in porky pets.
Chemeq thrown a lifeline
12 April, 2007 by Kate McDonaldA private financier may have come to the rescue of embattled animal health company Chemeq.
BIO 2007: Oz biotech looks set for a boomer
10 April, 2007 by Kate McDonaldLast year wasn't the best on record for the Australian biotechnology industry but this year and the next look much more promising. Share prices are up, investors are showing more interest and there are a lot of good stories to tell and sell.
New oncology application for Clinuvel
23 March, 2007 by Staff WritersClinuvel has identified a new application for its photoprotective drug, this time in cancer patients.
Synhumans for Peptech
19 March, 2007 by Staff WritersPeptech has released a new antibody technology platform called Synhumanisation.
Schering-Plough to buy Organon BioSciences
13 March, 2007 by Staff WritersContrary to recent moves by Big Pharma to shed workers and costs, Schering-Plough is buying up.
Border security for fruit flies
08 March, 2007 by Joanne FinlayUnderstanding molecular signatures of fruit flies could avert disaster for primary producers.
The ugly face of Ug99
01 March, 2007 by Joanne FinlayAustralian wheat growers have been warned that one of the world's most devastating diseases of wheat, stem rust, is back.
Antibody collaboration for EvoGenix and Vegenics
28 February, 2007 by Kate McDonaldAustralian biotech companies EvoGenix and Vegenics have entered into a technology collaboration agreement to target vascular endothelial growth factor D (VEGF-D), a mediator in angiogenesis.
Oral delivery of TNF blockers
22 February, 2007 by Kate McDonaldTNF blocker a second major application for Apollo Life Sciences' Oradel platform, currently in development for oral insulin.
Roche divides and sets out to conquer
07 February, 2007 by Kate McDonaldPharma giant Roche announces plans to restructure R&D activities and increase staff and spending.
